BRAF and melanoma: These effects may be explained by inhibition of the MAPK pathway given that MEK inhibitors are associated with responses in BRAF WT melanoma 27, 28, and other cell autonomous or cell non‐autonomous mechanisms, which is supported by our biomarker analysis.